*Dear Editor*,

The implementation of a standardized language in Nursing Care Plans (SNCP) allows for increased efficiency in nursing data management, and from our experience, its short-term effectiveness in patients with type 2 diabetes mellitus (T2DM) has been established.[@bib0005] Nevertheless, up-to-date data on the relationship between SNCP and patients' long-term health outcomes remain unclear. The aim of this study was to evaluate the effectiveness of implementing SNCP with NANDA-International (NANDA-I) nursing diagnoses[@bib0010] and interventions (NIC[@bib0015]) in the Computerized Clinical Records registration, in the improvement of metabolic, weight, and blood pressure control in patients with T2DM after 4-year follow-up.

This study was conducted as part of a broader project with its methodology being described elsewhere;[@bib0005] consisting in a 4-year prospective follow-up study carried out between March 2008 and February 2012. For the purposes of this paper we analyze only to the baseline and after 4-year of follow-up data. 30 primary health care centers (Madrid, Spain) consented to participate (23,488 T2DM outpatients), and data were collected from Computerized Clinical Records under routine clinical practice conditions.

18,320 patients were identified in the Usual Nursing Care Plans (UNCP) group, and 5168 in the SNCP group. However, the number of patients in the SNCP group with at least one HbA1c over the 4-year of follow-up was 2105, and for this reason we decided to select a random sample of an equal size in the UNCP group. Ensuring that patients in both groups were more likely to have collected all the necessary variables for them.

The study was approved by the research ethics committee of the Ramón y Cajal Hospital (Madrid), and it was determined that no informed consent was necessary in this type of study.

The two groups were homogeneous in gender, but not in age, diabetes evolution time and sedentary life style ([Table 1](#tbl0005){ref-type="table"}, first part). Patients in the SNCP group had a higher prevalence of dyslipidemia; received more treatment for diabetes (oral antidiabetics and insulin) and for cardiovascular disease, had poorer HbA1c (7.13% vs. 7.01%; *p* \< 0.001), and better Diastolic Blood Pressure (DBP) (75.9 mmHg vs. 76.5 mmHg; *p* \< 0.01), and LDL-Cholesterol (114.05 mg/dl vs. 116.5 mg/dl; *p* \< 0.01) than patients in the UNCP group.Table 1Basal characteristics of participants (first part: upper side section) and mean values (SD) and changes of basal and final parameters in both groups (second part: lower side section).UNCP (*n* = 2105)SNCP (*n* = 2105)*p* ValueSociodemographic variables Female gender % (*n*)53.6 (1128)54.3 (1143)0.643 Age (year) \[mean ± SD\]68.4 ± 1070 ± 100.000 Duration of DM (year) \[mean ± SD\]7.7 ± 6.38.6 ± 6.60.000 Duration of DM (year) \[median\]66.6 Current smoker % (*n*)19.9 (418)18.5 (390)0.273 Current drinker % (*n*)22.9 (483)24.4 (514)0.261 Sedentary life style % (*n*)1.3 (28)3.4 (72)0.000 BMI (kg/m^2^) \[mean ± SD\]29.8 ± 4.829.7 ± 4.50.461  DM medication profile % (*n*) Drug-free4.1 (87)3.1 (65)0.069 Oral antidiabetic73.8 (1554)77.5 (1632)0.005 Insulin16.4 (345)20.4 (429)0.001 Oral antidiabetic + insulin10.6 (224)13.9 (293)0.001  Other medication % (*n*) Statins58 (1220)61 (1284)0.045 Fibrates4 (85)4 (85)1.000 Diuretics27.6 (582)24.8 (523)0.039 Beta-blockers17.5 (368)15.5 (326)0.081 Calcium antagonist21.4 (450)22 (464)0.601 ACE inhibitors41 (863)38.8 (817)0.148 ARB23.6 (496)26.5 (557)0.030 Antiplatelet66.4 (1397)68.6 (1445)0.114  History of % (*n*) CHD11.5 (243)12.8 (270)0.203 Dyslipidemia51.3 (1080)54.5 (1148)0.036 Hypertension70.5 (1484)68.8 (1448)0.228 Retinopathy3.5 (74)4.3 (91)0.177 Nephropathy5.4 (113)5.5 (116)0.838 Neuropathy1.8 (37)1.7 (36)0.906UNCPSNCPUnadjusted SNCP effect (95%CI)[\*](#tblfn0005){ref-type="table-fn"}Adjusted SNCP effect (95%CI)[\*\*](#tblfn0010){ref-type="table-fn"}Hba1c (%) *mean* (SD) *N* patients2,1052,105 Basal7.01 (1.09)7.13 (1.05) 2 years6.96 (1.03)7.02 (0.98) 4 years6.96 (1.01)7.06 (1.05) Change−0.059 (0.99)−0.067 (1.0)−0.008 (−0.068 to 0.052)−0.06 (−0.54 to 0.41) *p* Value0.0070.0020.7890.792  LDL cholesterol (mg/dl) *mean* (SD)   *N* patients1,9311,968 Basal116.5 (29.8)114.05 (28.3) 2 years105.5 (27.04)103.1 (26.08) 4 years102.0 (27.3)101.2 (26.5) Change−14.7 (29.9)−12.7 (29.5)2.03 (−0.83 to 3.97)−6.24 (−19.7 to 7.21) *p* Value\<0.001\<0.0010.0410.358  SBP (mmHg) *mean* (SD) *N* patients2,0642,087 Basal134.1 (12.6)133.9 (12.05) 2 years132.07 (11.4)132.18 (11.2) 4 years132.4 (12.1)131.7 (11.7) Change−1.85 (12.3)−2.23 (11.7)−0.376 (−1.14 to 0.39)−4.59 (−10.1 to 0.91) *p* Value\<0.001\<0.0010.3370.101  DBP (mmHg) *mean* (SD) *N* patients2,0642,087 Basal76.5 (7.3)75.9 (6.9) 2 years74.8 (7.2)74.2 (6.6) 4 years74.6 (7.3)73.7 (6.7) Change−1.86 (7.4)−2.14 (6.9)−0.279 (−0.74 to 1.82)−3.60 (−6.18 to −1.03) *p* Value\<0.001\<0.0010.2350.007  BMI (kg/m^2^) *mean* (SD) *N* patients1,6501,860 Basal29.8 (4.8)29.7 (4.5) 2 years29.7 (4.9)29.5 (4.6) 4 years29.7 (5.1)29.5 (4.7) Change−0.33 (2.2)−0.32 (2.04)0.006 (−0.15 to 0.16)0.28 (−0.73 to 1.29) *p* Value\<0.001\<0.0010.9390.579[^1][^2][^3][^4]

At the 4-year follow-up, both groups experienced a modest decline in their parameter values ([Table 1](#tbl0005){ref-type="table"}, second part). The unadjusted effect of SNCP improved health outcomes, except for LDL cholesterol and BMI. After adjusting for baseline parameter values and age, duration of T2DM, type of treatment, physical inactivity and dyslipidemia, a lowering effect on all health outcomes was observed, except for BMI. DBP showed a significant and relevant reduction (decrease of 3.60 mmHg); however, Systolic Blood Pressure (SBP) showed a relevant but not significant reduction (decrease of 4.59 mmHg). Finally, those in the SNCP group saw a relative risk reduction of 32.3% (95%CI = 0.4--64.1%) and a absolute risk reduction of 1% (2% vs. 2.9%; *p* = 0.047) for stroke; however, increased incidence of Myocardial Infarction was seen, but not significant (1.3% vs. 1%; *p* = 0.39).

Therefore, after 4-year follow-up, patients in the SNCP group reached a persistent and significant reduction in DBP, but not significant in SBP, compared to patients in the UNCP group. Moreover, SNCP appears to be helpful in reducing the incidence of stroke. As reported in the VALUE study,[@bib0020] reductions in SBP of between 2 and 4 mmHg, during follow-up (4.2 years), had a very significant impact on the prevention of stroke in hypertensive patients at high risk, with patients with T2DM falling into this risk category. Finally, the strict blood pressure control observed in the UKPDS 38 study[@bib0025] was associated with better stroke risk reduction compared to the finding in study; however, patients in the UKPDS 38 were not followed under routine clinical practice conditions and the duration of treatment was over 8-years.
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[^1]: UNCP: Usual Nursing Care Plans; SNCP: Standardized Nursing Care Plans; HbA1c: Glycated hemoglobin; LDL cholesterol: low-density lipoprotein-Cholesterol; SBP: Systolic Blood Pressure; DBP: Diastolic Blood Pressure; BMI: Body Mass Index.

[^2]: The variable Change (mean at the 4-year follow-up value minus mean baseline value) was calculated in both groups for the following variables: HbA1c, LDL cholesterol, SBP, DBP, and BMI.

[^3]: Unadjusted SNCP effect was determined for these variables using the formula: mean value of the change in SNCP minus mean value of the change in UNCP.

[^4]: Adjusted SNCP effect was determinate with Covariance analysis methodology (ANCOVA). The covariables (adjustment variables) were: the baseline value for these variables and variables with statistically significant differences between groups at baseline or clinical relevance (gender).
